A clinical trial has indicated an effective treatment for critically ill COVID-19 patients. The study investigates the effects of using an anti-inflammatory protein, alpha-1 antitryspin (AAT), to treat COVID-19 patients who have progressed to acute respiratory distress syndrome (ARDS).